H.U. Group’s testing business returns to a ¥31m profit
H.U. Group provides outsourced testing to medical institutions, as well as diagnostic reagents and services such as sterilization. Its SRL subsidiary measures specimens from hospitals and clinics in its own laboratories, then sends the results back to those medical institutions.
Medical institutions entrust specimens to SRL. Its laboratories measure them and report the results.
Medical institution
Entrust specimens for testing
Specimens
SRL laboratory
1F · Automated testsPreparation and testing lines
2F / 3F · Specialized testsSpecialized testing, genetics and pathology
Results
Back to the medical institution
Receive the measured results
The equipment and people are schematic. The laboratory branches summarize Akiruno’s disclosed roles; they do not show every specimen passing through all floors or all SRL testing taking place at this site. Specialized floors also use automation.
A small profit sits behind a ¥13.598bn depreciation charge
The results presentation reports segment EBITDA of ¥13.7bn. The company defines EBITDA as operating profit plus depreciation and goodwill amortization. It adds back certain expenses; it is not a cash-flow measure. In this segment table, monetary amounts are rounded to units of ¥100 million, displaying operating profit as “0.” The financial results report the finer ¥1 million unit and show a ¥31m profit (definition and rounding, PDF p.2; LTS results, PDF p.11).
Testing growth, prices and daily operations reduced the loss
PROFIT IMPROVEMENT
The company’s explanation for the return to profit
A summary of the financial-results explanation for LTS in the year ended March 2026.
LTS returns to profitOperating profit of ¥31m
Grow testing salesGrowth in genetic and specialized testing, among other factors
Adjust selling pricesReview prices for the tests entrusted to the business
Improve testing operationsImprove how laboratory work is carried out
The diagram does not assign a profit contribution to each factor. Source: financial results, PDF p.4.
Group operating profit of ¥4.780bn covers a wider scope
THE VIEW AFTER THE NUMBERS
What the numbers suggest
H.U. Group’s testing business uses equipment and specialist staff to measure specimens arriving from medical institutions and return the results. In the year ended March 2026, testing growth, price adjustments and operating improvements brought it back to a ¥31m operating profit.
That remains a small surplus in a business carrying ¥13.598bn of depreciation. A laboratory’s ability to process specimens and its ability to earn a profit while keeping equipment and people at work need to be considered together.
JEOL’s electron-beam writers are used in making the gratings in DFB lasers for optical communications. Spot-beam orders and sales rose in the year ended March 2026, while fewer mask writers were sold and industrial-equipment sales declined. Following what each machine patterns, and where it sits in its customer’s production process, reveals different demand conditions within semiconductor-related equipment.
